(Q36304115)

13 August 2017

1 reference

title

Treatment strategies in nonalcoholic fatty liver disease (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

13 August 2017

1 reference

Herbert Tilg

1

1 reference

PubMed ID

16265156

13 August 2017

Arthur Kaser

series ordinal

2

1 reference

PubMed ID

16265156

13 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Nature Reviews Gastroenterology & Hepatology

13 August 2017

1 reference

13 August 2017

2

1 reference

13 August 2017

3

1 reference

13 August 2017

148-155

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpgasthep0116

13 August 2017

0 references

cites work

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Nonalcoholic fatty liver disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Effect on Hepatic Morphology of Treatment of Obesity by Fasting, Reducing Diets and Small-Bowel Bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Hepatic effects of dietary weight loss in morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Effect of weight control on hepatic abnormalities in obese patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Orlistat in the treatment of NASH: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Cytokines in alcoholic and nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Weight gain as a risk factor for clinical diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

Liver morphology and function tests in obesity and during total starvation

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

Clinical hepatic impairment after the duodenal switch

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

Nonalcoholic steatohepatitis in obesity: a reversible condition

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

Regression of hepatic steatosis in morbidly obese persons after gastric bypass

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0116

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0116

1 reference

13 August 2017

1 reference

PubMed ID

16265156